Skip to content

Effects of Continous Positive Airway Pressure (CPAP) in Hypertrophic Cardiomyopathy

Acute Hemodynamic Effects of Continous Positive Airway Pressure (CPAP) in Patients With Hypertrophic Cardiomyopathy

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01631006
Acronym
CPAPandHCM
Enrollment
26
Registered
2012-06-28
Start date
2012-01-31
Completion date
2013-04-30
Last updated
2014-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-obstructive Hypertrophic Cardiomyopathy, Obstructive Hypertrophic Cardiomyopathy

Keywords

CPAP, Hypertrophic cardiomyopathy, Blood Pressure, The focus of the present study is to evaluate the acute hemodynamic effects of CPAP in patients with non-obstructive and obstructive hypertrophic cardiomyopathy

Brief summary

Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiac disease, is a cause of disability including heart failure, atrial fibrillation, and sudden death, with an annual mortality varying from 1% to 6%. Obstructive sleep apnea (OSA) is extremely common among patients with established cardiovascular disease, including hypertension and atrial fibrillation and when present may contribute to worse cardiovascular outcome. Although patients with HCM do not necessarily have typical characteristics of patients with OSA, such as obesity and increasing age, there is recent evidence that OSA is extremely common among patients with HCM, with a prevalence ranging from 32% to 71%. The presence of OSA among patients with HCM is independently associated with worse structural and functional impairment of the heart, including atrial and aorta enlargement, worse New York Heart Association functional class, and worse quality of life. Therefore, the recognition and treatment of OSA is a new area of research that may impact in the management of patients with HCM.

Interventions

DEVICECPAP

A low or high CPAP pressure is delivered for 20 minutes

Sponsors

University of Sao Paulo
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* both genders * over 18 years-old * hemodynamically stable * with no other cardiac disease * consent form signed

Exclusion criteria

* presence of pacemaker * spontaneous withdrawal * previous cardiorespiratory arrest * atrial fibrilation during echocardiography

Design outcomes

Primary

MeasureTime frame
Cadiac performance by echocardiographyacutely

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 13, 2026